美国Glycominds
Glycominds公司通过分析针对每种疾病的特异性聚糖抗体生物标记物来区分这些疾病。例如检测多重硬化症的生物标记物，就是通过锚定在微孔滴定板上的糖分子固定8种检测用的聚糖抗体。Glycominds为炎症性肠道疾病提供了基于3种聚糖抗体标记物的经济的检验方法，并且计划进一步开发用于其他炎症性疾病的检测。

Glycominds Ltd. holds extensive knowledge and experience in the field of glycomics, utilized for the discovery and development of unique glycan biomarkers which enable high-value medical diagnostics. Glycominds is developing and commercializing a new class of novel blood tests which allow physicians to detect cancer earlier, predict autoimmune disease progression and decide on therapy regimen.

Autoimmune Decisions™

Our leading products are the IBDX®, a blood tests for Inflammatory Bowel Disease (IBD) diagnostics and Crohn's Disease severity assisting physicians in early and quick diagnosis and in fitting the appropriate course of treatment for CD patients, and the gMS™ a blood test for the prediction of patients with clinical isolated syndrome suggestive of MS converted to clinically definitive Multiple Sclerosis. This powerful test will enable physicians to take post-CIS treatment decisions.

We believe in advanced autoimmunity tests that will improve the quality of life for millions of patients